Cencora, Inc.

COR

CORE is a wholesale distributor operating in the pharmaceutical and health supplies industry.
It serves as a critical link in the healthcare supply chain, distributing essential medical products to pharmacies and retailers.

$372.14 +5.49 (+1.50%)

Updated: February 27, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model โœ“ Updated Daily

Investment Opinion: Should I buy COR Today?

Based on a comprehensive review of Corenergy Infrastructure's (COR) investment profile, a HOLD recommendation is advised. The analysis reveals conflicting signals between operational strengths and significant financial and valuation concerns.

Technical & Fundamental Snapshot Technically, COR is trading near its 52-week high, suggesting limited short-term upside momentum and potential overbought conditions. Fundamentally, its recent return to profitability is overshadowed by weak liquidity metrics, a negative cash flow to debt ratio, and exceptionally thin profit margins that highlight operational fragility.

Valuation & Risk Assessment Valuation presents the most significant hurdle, with extreme multiples (P/E of 43.48, P/B of 34.03) that are difficult to justify, especially paired with a negative PEG ratio indicating a lack of earnings growth to support the premium. While its low beta offers some defensive appeal against market volatility, the fundamental risks related to cash flow and debt service are substantial.

Recommendation COR is not currently worth buying. The stock's high valuation is not supported by its growth prospects or financial health. Investors should wait for a more attractive entry point and clearer signs of improved cash flow generation and sustainable profitability before considering a position. The current risk/reward profile is unbalanced.

CTA Banner

COR 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis provided, here is the 12-month outlook for COR:

The outlook for COR over the next 12 months is challenged, with the key catalyst being its continued operational execution to demonstrate that its recent return to profitability is sustainable, which could help justify its premium valuation. However, significant risks dominate, primarily its extreme valuation multiples, fragile profit margins, and concerning cash flow relative to debt, which create a high hurdle for price appreciation. Given the lack of a discernible analyst target price and the unbalanced risk/reward profile, investors should anticipate the stock to trade within a wide range, likely between $300 and $380, as the market weighs its defensive low-beta characteristics against its substantial fundamental weaknesses. A break above the current levels near the 52-week high appears unlikely without a material improvement in financial health.

Wall Street Consensus

Most Wall Street analysts are optimistic about Cencora, Inc.'s 12-month outlook, with consensus target around $372.14, indicating expected upside potential.

Average Target
$372.14
18 analysts
Implied Upside
+0%
vs. current price
Analyst Count
18
covering this stock
Price Range
$298 - $484
Analyst target range
Buy Buy
14 (78%)
Hold Hold
3 (17%)
Sell Sell
1 (6%)

Bulls vs Bears: COR Investment Factors

Overall, COR has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Stock outperforming medical peers: COR is showing stronger performance compared to other medical stocks this year.
  • Major acquisition boosting growth: $5B OneOncology acquisition expands oncology services and market reach.
  • Raised long-term EPS guidance: Company increased adjusted EPS growth forecast to 10-14% long-term.
  • JPMorgan price target increase: JPMorgan raised price target following positive financial model update.
  • Institutional investor confidence: Public Sector Pension Investment Board increased holdings by 54.8%.
Bearish Bearish
  • Analyst downgrade to hold: Recent analyst downgrade to hold rating caused 4.3% stock drop.
  • Major institutional selling: Close Asset Management cut its stake in COR by 73.4%.
  • High acquisition spending: $5B acquisition creates significant capital expenditure and integration risk.
  • Debt assumption from acquisition: Company will retire $1.3B of OneOncology debt, increasing leverage.
Reward Banner

COR Technical Analysis

COR has demonstrated strong performance with substantial gains from its 52-week low, though recent momentum has been relatively muted.

Over the past one and three months, COR has posted positive returns of 2.95% and 1.26% respectively. However, the stock has underperformed the broader market by 4.37% over the three-month period, indicating weaker relative strength despite its low beta of 0.685 suggesting less volatility than the market.

Currently trading at $366.65, COR sits near the top of its 52-week range ($248.11-$377.54), approximately 3% below its high. This proximity to the peak, combined with a modest maximum drawdown of -11.95% over the past year, suggests the stock is not in an oversold condition but may be approaching overbought territory.

๐Ÿ“Š Beta
0.69
0.69x market volatility
๐Ÿ“‰ Max Drawdown
-11.9%
Largest decline past year
๐Ÿ“ˆ 52-Week Range
$249-$378
Price range past year
๐Ÿ’น Annual Return
+46.8%
Cumulative gain past year
Period COR Return S&P 500
1m +6.2% -1.4%
3m +1.8% +4.1%
6m +22.5% +7.5%
1y +46.8% +15.4%
ytd +9.8% +0.4%

COR Fundamental Analysis

Revenue & Profitability COR demonstrated improved profitability in Q1 2026, with revenue growing to $85.9 billion and net income recovering to $559.6 million from a loss in the prior quarter. However, the company operates on thin margins, with a net profit margin of just 0.65%, though this represents a significant improvement over Q4 2025's negative margin. The gross profit ratio improved marginally to 3.27%, indicating slight improvement in core cost management.

Financial Health The company's financial health shows mixed signals, with a strong interest coverage ratio of 10.9x but concerning liquidity metrics. The current ratio below 1 (0.92) and quick ratio of 0.51 indicate potential short-term liquidity constraints. Notably, the cash flow to debt ratio is negative (-0.29), suggesting operational cash flow isn't sufficient to cover debt obligations, which is a significant concern.

Operational Efficiency COR shows strong returns with an impressive ROE of 29.3%, though this is supported by high financial leverage as evidenced by the 41.1x equity multiplier. Asset turnover of 1.10 demonstrates reasonable efficiency in generating revenue from assets. The negative cash conversion cycle of -7.4 days indicates the company collects from customers before paying suppliers, which is operationally favorable despite the negative operating cash flow per share.

Quarterly Revenue
$85.9B
2025-12
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
3.6%
Latest Quarter
Free Cash Flow
$-0.6B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is COR Overvalued?

Based on available metrics, COR appears significantly overvalued. The TTM PE ratio of 43.48 is exceptionally high for most companies, suggesting a premium price relative to current earnings. This premium is tempered slightly by the lower forward PE of 29.30, but remains elevated. The extreme PB ratio of 34.03 and EV/EBITDA of 68.86 further underscore this overvaluation, indicating the market is pricing the stock far above its book value and operating earnings. The negative PEG ratio of -0.11, resulting from negative estimated earnings growth, presents a major concern as it implies the company's growth trajectory does not justify its high earnings multiple.

Unfortunately, a peer comparison cannot be conclusively made due to the unavailability of industry average data. However, these valuation metrics are typically considered high across most sectors, suggesting COR trades at a substantial premium. The negative PEG ratio is particularly notable, as it diverges from the typical growth justification for high-multiple stocks and would likely stand out even in a high-growth industry.

PE
43.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -45ร—-3303ร—
vs. Industry Avg
N/A
Industry PE ~N/Aร—
EV/EBITDA
68.9x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk: COR exhibits below-average volatility with a Beta of 0.685, indicating it is approximately 30% less volatile than the broader market. The relatively modest maximum drawdown of -11.95% over the past year further underscores its comparatively stable price history, suggesting lower volatility risk for investors.

Other Risks: The apparent absence of significant short interest implies that bearish speculative pressure on the stock is currently negligible. A notable risk consideration is the stockโ€™s liquidity profile, which was not provided; potential low trading volume could pose challenges for entering or exiting positions without impacting the price.

FAQs

Is COR a good stock to buy?

Neutral to Bearish. While the stock benefits from strong analyst support (all 18 rate it a buy) and a growth-focused acquisition, it is significantly overvalued (high P/E, P/B ratios) and exhibits weak financial health with negative cash flow relative to debt. This mix of optimism and underlying risk makes it suitable primarily for risk-tolerant, growth-oriented investors who believe the long-term strategy will overcome current valuation and liquidity concerns.

Is COR stock overvalued or undervalued?

Based on the metrics provided, COR appears significantly overvalued. Key valuation ratios like the trailing PE of 43.48, forward PE of 29.30, and an extreme Price-to-Book of 34.03 are exceptionally high and would be considered a substantial premium in almost any industry. The primary reason for this overvaluation appears to be a major disconnect, as the negative PEG ratio (-0.11) indicates negative estimated earnings growth, which starkly contradicts the high earnings multiples and fails to provide the typical growth justification for such a premium valuation.

What are the main risks of holding COR?

Based on the provided information, here are the key risks of holding COR:

1. Financial Liquidity Risk: The company faces potential short-term liquidity constraints, evidenced by a current ratio below 1 (0.92) and a negative cash flow to debt ratio (-0.29), indicating operational cash flow is insufficient to cover debt obligations. 2. Valuation and Momentum Risk: The stock is trading near the top of its 52-week range and has recently underperformed the market, suggesting it may be approaching overbought territory with limited near-term upward momentum. 3. High Financial Leverage Risk: The impressive Return on Equity (29.3%) is supported by an extremely high equity multiplier (41.1x), indicating the company's performance is heavily reliant on debt, which amplifies risk in a downturn.

What is the price forecast for COR in 2026?

Based on the provided analysis, Corenergy's forecast through 2026 is highly uncertain and contingent on its ability to rectify significant financial weaknesses.

My target price range for 2026 is $320-$420, encompassing a base case near the lower end and a bull case dependent on successful operational improvements. Key growth drivers are the sustainability of its recent return to profitability, maintaining its strong Return on Equity, and leveraging its operationally favorable negative cash conversion cycle.

The primary assumptions are that management can improve thin margins and, critically, generate positive operational cash flow to address the concerning cash flow-to-debt ratio. Given the extreme leverage and current negative cash flow, this forecast carries substantial downside risk, and the stock is unlikely to see sustained appreciation without a material improvement in its financial health.